Iconovo Valuation Multiples

Iconovo Overview

About Iconovo

Iconovo AB develops new inhaled medicinal products in collaboration with international pharmaceutical companies. The company provides several types of patent-protected inhalers that can generate commercial opportunities in the development of novel pharmaceuticals and vaccines and at patent expirations for established pharmaceuticals. The project is a generic version of the asthma and COPD product Symbicort.

Founded

2013

HQ

Employees

25

Website

iconovo.se

Sectors

Medical DevicesHealthTech

Financials (LTM)

Revenue: $996K

EBITDA: ($4M)

EV

$6M

Valuation Multiples

Multiples.vc

Start free trial

Iconovo Financials

Iconovo reported last 12-month revenue of $996K and negative EBITDA of ($4M).

In the same LTM period, Iconovo generated $661K in gross profit, ($4M) in EBITDA losses, and had net loss of ($3M).

Iconovo P&L

In the most recent fiscal year, Iconovo reported revenue of $121K and EBITDA of ($4M).

Iconovo expects next 12-month revenue of XXX and NTM EBITDA of XXX

Iconovo Stock Performance

Iconovo has current market cap of $7M, and enterprise value of $6M.

Iconovo's stock price is $0.13.

Iconovo Valuation Multiples

Iconovo trades at 6.1x EV/Revenue multiple, and (1.7x) EV/EBITDA.

Iconovo Financial Valuation Multiples

As of April 20, 2026, Iconovo has market cap of $7M and EV of $6M.

Equity research analysts estimate Iconovo's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Iconovo has a P/E ratio of (2.0x).

Iconovo Margins & Growth Rates

Iconovo's revenue in the last 12 month grew by 123%.

Iconovo's revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $0.2M for the same period.

Iconovo's rule of 40 is 2364% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Iconovo's rule of X is 6034% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Iconovo Public Comps

See public comps and valuation multiples for other Medical Devices comps.

Iconovo M&A Activity

Iconovo acquired XXX companies to date.

Last acquisition by Iconovo was on XXXXXXXX, XXXXX. Iconovo acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Iconovo Investment Activity

Iconovo invested in XXX companies to date.

Iconovo made its latest investment on XXXXXXXX, XXXXX. Iconovo invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).